These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Mechanisms of tumor regression induced by low doses of interleukin-2.
    Author: Maas RA, Dullens HF, Den Otter W.
    Journal: In Vivo; 1991; 5(6):637-41. PubMed ID: 1810449.
    Abstract:
    We have demonstrated that local treatment with low doses of IL-2 can cure mice bearing a large burden of metastasized SL2 lymphoma. Different mechanisms lead to rejection of ascitic SL2 tumor and solid s.c. SL2 tumor. For local rejection of ascitic tumor cytotoxic T-lymphocytes were essential, whereas the cytotoxic activity of macrophages was also important for tumor rejection. In distant solid tumors very few infiltrating lymphocytes and macrophages were present. Nevertheless, IL-2 treatment rapidly induced necrosis that seemed to be caused by stasis of blood flow in the tumors. This may be mediated by the local release of cytokines like TNF. We conclude that both cytotoxic activity and the production of cytokines by T-cells is essential for IL-2 induced systemic tumor rejection.
    [Abstract] [Full Text] [Related] [New Search]